ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

LQDA Liquidia Corporation

12.37
-0.58 (-4.48%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,125,764
Bid Price 12.35
Ask Price 12.63
News -
Day High 13.0699

Low
5.71

52 Week Range

High
16.99

Day Low 12.40
Company Name Stock Ticker Symbol Market Type
Liquidia Corporation LQDA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.58 -4.48% 12.37 20:00:00
Open Price Low Price High Price Close Price Prev Close
12.97 12.40 13.0699 12.55 12.95
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
15,401 1,125,764 $ 12.69 $ 14,288,877 - 5.71 - 16.99
Last Trade Time Type Quantity Stock Price Currency
19:47:48 1 $ 12.62 USD

Liquidia (LQDA) Options Flow Summary

Overall Flow

Bullish

Net Premium

327k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Liquidia Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
954.91M 76.03M - 17.49M -78.5M -1.03 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Liquidia News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LQDA Message Board. Create One! See More Posts on LQDA Message Board See More Message Board Posts

Historical LQDA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.4414.2412.4013.33927,135-1.07-7.96%
1 Month15.7515.9012.4014.44906,215-3.38-21.46%
3 Months12.7016.9912.4014.58836,094-0.33-2.60%
6 Months6.1616.996.0612.02976,0376.21100.81%
1 Year6.9316.995.7110.41760,9605.4478.50%
3 Years2.8716.992.257.01758,1199.50331.01%
5 Years8.0716.992.256.13640,6854.3053.28%

Liquidia Description

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.

Your Recent History

Delayed Upgrade Clock